A minigene DNA vaccine encoding peptide epitopes derived from Galectin-1 has protective antitumoral effects in a model of neuroblastoma

Immunotherapy of Pediatric Solid Tumors: Treatments at a Crossroads, with an Emphasis on Antibodies

(2020) Dana L. Casey et al.   Cancer Immunology Research

Role of Galectins in Tumors and in Clinical Immunotherapy

(2018) Feng-Cheng Chou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma

(2018) Kai Chen et al.   PEDIATRIC BLOOD & CANCER

Targeting of MYCN by means of DNA vaccination is effective against neuroblastoma in mice

(2015) Alexander Stermann et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma

(2013) Elisa Berger et al.   CANCER LETTERS

Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments

(2011) Rocio Soldati et al.   INTERNATIONAL JOURNAL OF CANCER

Galectins: regulators of acute and chronic inflammation

(2010) Fu-Tong Liu et al.   Annals of the New York Academy of Sciences

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survivin minigene DNA vaccination is effective against neuroblastoma

(2009) Stefan Fest et al.   INTERNATIONAL JOURNAL OF CANCER

Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma

(2009) N. Huebener et al.   MOLECULAR CANCER THERAPEUTICS

Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness

(2009) F Cimmino et al.   ONCOGENE

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

(2008) Susan L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

(2008) Andrew DJ Pearson et al.   LANCET ONCOLOGY

A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity

(2008) N. Huebener et al.   MOLECULAR CANCER THERAPEUTICS